Abstract
Valproic acid (sodium valproate) is widely used as a first-line antiepileptic agent. As with many antiepileptic drugs, there are a number of consequences associated with the use of valproic acid in women of child-bearing potential. Most pregnancies have a favourable outcome in women with epilepsy, and these women should not be discouraged from becoming pregnant. Unlike many other antiepileptic drugs, valproic acid has no significant pharmacokinetic interactions with the steroid hormones used in oral contraceptives. During pregnancy, the major risks to mother and child result from loss of seizure control on the one hand, and an elevated risk of major congenital malformations due to antiepileptic drug treatment on the other. In particular, an elevated risk of major congenital malformations associated with valproic acid use has been a consistent finding in studies of patient registries and several large case series. In addition, developmental delay, characterised by low verbal IQ, has also been reported in children exposed to valproic acid in utero, although the relative risk is not precisely known. For these reasons, pregnancies in women being treated with valproic acid need to be planned, and the benefit-risk ratios associated with continuing valproic acid or changing treatment need to be discussed with the patient. When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus. These include the use of the lowest possible effective dose of valproic acid in monotherapy (ideally <1000 mg/day), appropriate folic acid supplementation and close antenatal monitoring. Regular counselling is a prerequisite for informed planning of pregnancies and optimisation of the probability of a healthy outcome. Future research on valproic acid and pregnancy should involve risk assessment in large, population-based prospective studies.
Similar content being viewed by others
References
Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester (MN). Mayo Clin Proc 1996; 71: 576–86
Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16: 165–70
Groupe CAROLE (Coordination Active du Reseau Observatoire Longitudinal de l’Epilepsie). Treatment of newly diagnosed epileptic crises: a French experience. Rev Neurol 2001; 157: 1500–12
Moran NF, Poole K, Bell G, et al. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure 2004; 13: 425–33
Semah F, Picot MC, Derambure P, et al. The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey. Epileptic Disord 2004; 6: 255–65
Thomas P, Genton P, Gelisse P, et al. Juvenile myoclonic epilepsy. In: Roger J, Bureau M, Dravet C, eaet al., editors. Epileptic syndromes in infancy, childhood and adolescence. 3rd ed. Eastleigh: John Libbey & Co Ltd, 2002: 335–55
Janz D, Dam M, Richens A. Epilepsy, pregnancy and the child. NewYork: Raven, 1982
Morrow JI, Russell A, Gutherie E, et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2005 Sep 12 [Epub ahead of print]
Crawford P. Epilepsy and pregnancy. Seizure. 2002; 11Suppl. A: 212–9
Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop. Epilepsy Res 2003; 52: 147–87
Patsalos PN. Pharmacokinetic and pharmacodynamic interactions: principles and interpretative pitfalls. Epileptologia 1998; 6: 9–19
Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263–72
Blum D, Sidhu J, Bulsara S, et al. A bi-directional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive (COC) pill in healthy subjects. American Pain Society 2005, Abstract 901
Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151–4
Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570–1
Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives. A national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72: 114–5
Krauss GL, Brandt J, Campbell M, et al. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 1996; 46: 1534–9
Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33: 23–9
Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975 Aug; 87(2): 285–90
Lindhout D, Omtzigt JG. Pregnancy and the risk of teratogenicity. Epilepsia 1992; 33Suppl. 4: S41–8
Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68: 18–24
Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145–58
Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132–8
Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739–46
Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004; 27: 197–202
Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004; 45: 1171–5
Craig JJ, Morrow JI. New antiepileptic drugs: register of women who take the drugs during pregnancy has been set up [letter]. BMJ 1997; 314: 603
Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981–90
Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231–6
Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003; 60: 575–9
Bergmann A, Schmidt D, Hutt HG, et al. Epilepsy treatment with sustained-release formulation of valproate: experience with 1172 patients. Akt Neurol 1999; 26: 1–5
Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174–6
Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61: 673–8
Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–5
Vajda FJ, O’Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10: 543–9
Vajda FJ, O’Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11: 854–8
Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955–60
Russell AJ, Craig JJ, Morrison P, et al. UK epilepsy and pregnancy group [abstract]. Epilepsia 2004; 45: 1467
Craig JJ, Russell A, Parsons L, et al. The UK Epilepsy and Pregnancy Register: update of results 1996-2003 [abstract]. Epilepsia 2004; 45Suppl. 7 229
Koch S, Jager-Roman E, Losche G, et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr 1996; 85: 739–46
Wide K, Winbladh B, Tomson T, et al. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev Med Child Neurol 2000; 42: 87–92
Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37: 489–97
Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 15–21
Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39: 251–9
Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002; 11: 512–8
Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575–83
Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28–32
Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry [abstract]. Epilepsia 2004; 45: 1465
A North American Registry for Epilepsy and Pregnancy: a unique public/private partnership of health surveillance. Epilepsia 1998; 39: 793–8
Vajda F, Lander C, O’Brien T, et al. Australian Pregnancy Registry of Women taking antiepileptic drugs [abstract]. Epilepsia 2004; 45: 1466
Beghi E, Annegers JF; Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422–5
Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004; 45: 1463–4
Thomas SV, Indrani L, Devi GC, et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurol India 2001; 49: 60–6
Tennis P, Eldridge RR, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161–7
Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 1999; 57: 535–44
Jones KLJ, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661–6
Vestermark V, Vestermark S. Teratogenic effect of carbamazepine. Arch Dis Child 1991; 66: 641–2
DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473–81
Winter RM, Donnai D, Burn J, et al. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987; 24: 692–5
Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993; 69(3 Special No): 288–91
Christianson AL, Chesler N, Kromberg JG. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 1994; 36: 361–9
Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995; 32: 724–7
Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171–85
Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; I(7954): 272–5
Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89: 662–8
Gaily E, Kantola-Sorsa E, Granstrom ML. Intelligence of children of epileptic mothers. J Pediatr 1988; 113: 677–84
Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32: 403–14
Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767–70
Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40: 1237–43
Touwen BCL. Examination of the child with minor neurological dysfunction. Clin Dev Med 1979; 71: 1–72
Shorvon SD. Longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1517–8
Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol 1997 Sep; 39(9): 632–4
Williams G, King J, Cunningham M, et al. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001 Mar; 43(3): 202–6
Rasalam AD, Hailey H, Williams JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005 Aug; 47(8): 551–5
Adab N, Tudur SC, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 2004; (3): CD004848
Tettenborn B, Genton P, Polson D. Epilepsy and women’s issues: an update. Epileptic Disord 2002; 4Suppl. 2: S23–31
Royal College of Physicians. Adults with poorly controlled epilepsy: clinical guidelines for treatment and practical tools for aiding epilepsy management. London: Royal College of Physicians, 1997
Nau H, Spielmann H. Embryotoxicity testing of valproic acid. Lancet 1983 Apr 2; 1(8327): 763–4
Barre J, Berger Y. Pharmacokinetics of a newly developed sustained-release form of sodium valproate. In: Chadwick D, editor. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy, International Congress and Symposium Series No. 152. London: Royal Society of Medicine Services, 1989: 178–84
Berto P. Quality of life in patients with epilepsy and impact of treatments. Pharmacoeconomics 2002; 20(15): 1039–59
Dean JC, Moore SJ, Osborne A, et al. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 1999 Sep; 56(3): 216–20
Quality Standards Committee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Report of the quality standards committee of the American Academy of Neurology. Neurology 1998; 51: 944–8
MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131–7
Padmanabhan R, Shafiullah MM. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 2003; 43: 29–40
Elmazar MM, Thiel R, Nau H. Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice. Fundam Appl Toxicol 1992 Apr; 18(3): 389–94
Trotz M, Wegner C, Nau H. Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse. Life Sci 1987 Jul 6; 41(1): 103–10
Dawson JE, Raymond AM, Winn LM. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol Appl Pharmacol 2005 Aug 19 [Epub ahead of print]
Hansen DK, Grafton TF, Dial SL, et al. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Teratology 1995 Nov; 52(5): 277–85
Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608–14
Hendel J, Dam M, Gram L, et al. The effects of carbamazepine and valproate on folate metabolism in man. Acta Neurol Scand 1984 Apr; 69(4): 226–31
Goggin T, Gough H, Bissessar A, et al. A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy. Q J Med 1987 Nov; 65(247): 911–9
Karabiber H, Sonmezgoz E, Ozerol E, et al. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 2003 Mar; 25(2): 113–5
Bentsen KD, Gram L, Veje A. Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate: a controlled study. Acta Neurol Scand 1983 Apr; 67(4): 235–41
Gidal BE, Tamura T, Hammer A, et al. Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 2005 May; 64(3): 161–6
Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997 Jan; 145(1): 109–12
Geda G, Caksen H, Icagasioglu D. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Acta Neurol Belg 2002 Sep; 102(3): 122–6
Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8: 75–8
Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42Suppl. 5: 32–42
Craig J, Morrison P, Morrow J, et al. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999; 8: 253–4
Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42Suppl. 5: 149–60
Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999; 8: 201–17
Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61Suppl. 2: S23–6
Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med 2004; 71: S25–37
Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982; 7: 336–52
Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992; 42(4 Suppl. 5): 12–6
Malone FD, D’Altone ME. Drugs in pregnancy: anticonvulsants. Semin Perinatol1997; 21: 114–23
Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci 1998; 23: 223–8
Shorvon S. Antiepileptic drug therapy during pregnancy: the neurologist’s perspective. J Med Genet 2002; 39: 248–50
Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985; 26: 631–5
Sabers A. Complications during pregnancy and delivery. In: Janz D, Dam M, Richens A, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 81–5
Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22(1): 62–5
Anderson GD, Lin YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997 Aug; 87(2): 252–6
Kaaja E, Kaaja R, Matila R, et al. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002 Feb 26; 58(4): 549–53
Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003; 61(6 Suppl. 2): S35–42
Acknowledgements
Funding for editorial assistance for the preparation of this article was provided by Sanofi-Aventis, the manufacturer of valproic acid.
Dr Pierre Genton has received lecturing and consultancy fees from Sanofi-Aventis, Novartis, GlaxoSmithKline, UCB and Janssen-Cilag over the past 5 years. He has also received a research grant from UCB and participated in the ‘Access to Medication’ international programme of Sanofi-Aventis in developing countries.
Dr Franck Semah has received lecturing and consultancy fees from Sanofi-Aventis, Novartis, GlaxoSmithKline, Pfizer, UCB and Janssen-Cilag over the past 5 years.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Genton, P., Semah, F. & Trinka, E. Valproic Acid in Epilepsy. Drug-Safety 29, 1–21 (2006). https://doi.org/10.2165/00002018-200629010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200629010-00001